

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Epidermal growth factor receptor (EGFR); kelch domain containing 8A (KLHDC8A)	<p>Studies in mice and in cell culture suggest that inhibiting KLHDC8A could help treat gliomas that have acquired resistance to EGFR-targeted therapies. In mice with EGFR-resistant glioma cells, small hairpin RNA-mediated knockdown of <i>Klhdc8a</i> reduced tumor formation compared with that seen using control shRNA. Next steps include studying how KLHDC8A is regulated in EGFR-resistant tumors.</p> <p>GlobeImmune Inc.'s GI-3000, an EGFR inhibitor, is in preclinical testing to treat brain cancer. At least five other companies have EGFR inhibitors in development to treat cancer.</p> <p>SciBX 3(5); doi:10.1038/scibx.2010.142 Published online Feb. 4, 2010</p>	<p>Work unpatented; available for licensing from the Ludwig Institute for Cancer Research Office of Intellectual Property and Technology Licensing</p> <p>Contact: Jonathan Skipper, Ludwig Institute for Cancer Research, New York, N.Y. e-mail: jskipper@licr.org</p>	<p>Mukasa, A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 18, 2010; doi:10.1073/pnas.0914356107</p> <p>Contact: Frank Furnari, University of California, San Diego, La Jolla, Calif. e-mail: ffurnari@ucsd.edu</p> <p>Contact: Webster K. Cavenee, same affiliation as above e-mail: wcavenee@ucsd.edu</p>